Punto Health’s Post

Today, the #FDA Peripheral and Central Nervous System Drugs Advisory Committee voted to endorse #donanemab. If approved, this would be the second disease-modifying drug for #Alzheimer's to receive full approval, expanding the arsenal of available drugs needed to treat Alzheimer’s with #CombinationTherapy. “Today’s vote offers hope that donanemab will be approved in the coming months, but it’s important to look at this milestone in the larger treatment landscape for Alzheimer’s, which will entail a combination therapy and #PrecisionMedicine approach,” notes Howard Fillit, MD, Co-Founder and Chief Science Officer of the ADDF. “If approved, donanemab will expand the first class of disease-modifying drugs, serving as the building blocks for future generations of drugs. #AntiAmyloids are not a silver bullet, but they offer opportunities for patients to modify the course of the disease while the field works towards developing more #novel therapies that target the underlying biology.” Read the ADDF’s statement on how this vote affects the larger Alzheimer’s research landscape here: https://bit.ly/3yTcJ1N